AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29391819
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow rate (HFR) at 10.4 mL/s
Trial: 29391819
Drug: Low flow
RxNorm normalized name: high mallow flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow rate (LFR) at 1.7 mL/s
Trial: 29392234
Drug: Bupivacaine lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine lozenges (25 mg) taken up to every 2 hours for 7 days plus standard pain treatment minus topical lidocaine
Trial: 29392234
Drug: Standard pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pain treatment including topical lidocaine
Trial: 29392418
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC) supplementation (1 g/day)
Trial: 29392418
Drug: Acute methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute methionine loading (MetLo) (0.1 g Met/kg mass weight)
Trial: 29392450
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate (IV AS) at a maximum tolerated dose (MTD) of 18 mg/kg
Trial: 29392450
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate (IV AS) at dosages of 12 mg/kg, 18 mg/kg, and 25 mg/kg
Trial: 29393183
Drug: Chemotherapy (PCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (PCV or temozolomide)
Trial: 29394124
Drug: Pomalidomide plus
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide plus low-dose dexamethasone (LoDEX)
Trial: 29394884
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG, n = 80), no treatment, usual recreational activities
Trial: 29394907
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation strategy (VT set at 6-8 ml/kg, PEEP at 6-8 cmH2O)
Trial: 29394907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (VT set at 10-12 ml/kg, no PEEP or recruitment maneuvers)
Trial: 29394908
Drug: daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily calorie restriction (reduce habitual daily energy intake by 25%)
Trial: 29394908
Drug: intermittent fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent fasting with calorie restriction (alternate between 24-hour periods of fasting and feeding to 150% of habitual daily energy intake)
Trial: 29394908
Drug: intermittent fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent fasting without calorie restriction (alternate between 24-hour periods of fasting and feeding to 200% of habitual daily energy intake)
Trial: 29394918
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for up to 24 months; follow-up includes testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually, and renal function monitoring six-monthly.
Trial: 29395867
Drug: Chemotherapy (platinum-based)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (platinum-based)
Trial: 29395867
Drug: Chemotherapy (taxane)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (taxane)
Trial: 29395867
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment during pregnancy
Trial: 29396094
Drug: R-CHOP (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (rituximab plus cyclophosphamide [750 mg/m2], doxorubicin, vincristine, and prednisone) followed by radioimmunotherapy and maintenance rituximab for 4 years
Trial: 29396857
Drug: FLAI-GO induction
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAI-GO induction regimen (fludarabine 30 mg/sqm, cytarabine 2 g/sqm, idarubicin 10 mg/sqm, Gemtuzumab-Ozogamicin 3 mg/sqm)
Trial: 29397139
Drug: Presurgical antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical antiplatelet therapy (APT) prescribed in 95% of procedures; preoperatively discontinued in 15%.
Trial: 29397225
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination with polygeline-free inactivated TBE vaccine (TBEvac)
Trial: 29399054
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (CT) 3.5 mg/kg
Trial: 29399258
Drug: Ingenol Disoxate
RxNorm normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingenol Disoxate (LEO 43204), treatment duration not specified
Trial: 29401002
Drug: Alpelisib 400
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib 400 mg once daily
Trial: 29401002
Drug: Alpelisib 150
RxNorm normalized name: alpelisib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 150 mg twice daily
Trial: 29401002
Drug: Alpelisib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (various doses)
Trial: 29401080
Drug: Intermittent oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent oxytocin pretreatment (alternating 10(-5) M and physiological salt solution every 15 minutes for 2 hours)
Trial: 29402064
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of intravenous alteplase
Trial: 29402243
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs), specifically gefitinib
Trial: 29402319
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and treatment programme combined with flash glucose monitoring device
Trial: 29402761
Drug: Fitbit One
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitbit One worn daily throughout the 12-week intervention
Trial: 29404331
Drug: 17.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 g/day cooked navy bean powder
Trial: 29404331
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day heat-stabilized rice bran
Trial: 29404331
Drug: 9 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g/day navy beans and 8 g/day rice bran
Trial: 29404713
Drug: OnabotulinumtoxinA 155
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles (108 weeks)
Trial: 29405626
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg once daily for 6 weeks, followed by random assignment to either placebo or atrasentan 0.75 mg/day for responders (≥30% UACR decrease)
Trial: 29405626
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg/day for non-responders (<30% UACR reduction)
Trial: 29406378
Drug: Pediatric residents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric residents as first laryngoscopists in PICUs with a Pediatric Critical Care Medicine fellowship
Trial: 29406378
Drug: Pediatric residents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric residents as first laryngoscopists in PICUs without a Pediatric Critical Care Medicine fellowship
Trial: 29406378
Drug: ICUs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICUs with a Pediatric Critical Care Medicine fellowship
Trial: 29406378
Drug: ICUs without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICUs without a Pediatric Critical Care Medicine fellowship
Trial: 29406772
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol combination
Trial: 29406772
Drug: Inhaled treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treatments (including vilanterol and fluticasone furoate/vilanterol)
Trial: 29406851
Drug: Dobutamine Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine Stress Echocardiography (DSE) with peak stress mean gradient (MG) ≥40 mm Hg
Trial: 29406851
Drug: Composite of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite of peak stress MG ≥40 mm Hg and peak stress aortic valve area (AVA) ≤1 cm
Trial: 29407124
Drug: Conventional strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strategy based on treatment of coronary artery disease only with standard of care (n=258)
Trial: 29407124
Drug: Conventional strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strategy based on treatment of coronary artery disease only with standard of care
Trial: 29409025
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (Nordic diet recommendations and at least 150 minutes of moderate exercise weekly)
Trial: 29409462
Drug: Standard treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatments (endoscopy and surgery)
Trial: 29409462
Drug: Multimodal treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatments (including chemotherapy, targeted therapies, immunotherapy, radiotherapy, and surgery)
Trial: 29410385
Drug: PENFS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENFS treatment group (10 subjects)
Trial: 29410385
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy control group (10 subjects)
Trial: 29411338
Drug: Infusion safety
RxNorm normalized name: SET,INFUSION SAFETY BRAUN #4252535-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion safety intervention bundle
Trial: 29412688
Drug: Long-Acting β-Agonist/Inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-Acting β-Agonist/Inhaled Corticosteroid
Trial: 29413684
Drug: HER family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER family inhibitors (trastuzumab, lapatinib, afatinib)
Trial: 29413684
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (lapatinib or afatinib)
Trial: 29413684
Drug: Other molecularly
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Other molecularly targeted agents (mTOR, PI3K, NOTCH inhibitors, chemotherapy)
Trial: 29414995
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment cohorts
Trial: 29415190
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily alone (days 1-4)
Trial: 29415190
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily with isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19)
Trial: 29416368
Drug: Nutriage day
RxNorm normalized name: NuTriaRX CreamPak KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutriage day cream (morning application)
Trial: 29416368
Drug: Nutriage night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutriage night cream (evening application)
Trial: 29416652
Drug: Rituximab 375mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4, along with HD-MTX 3.5g/m2, vincristine, procarbazine, cytarabine, and dexamethasone taper.
Trial: 29416986
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m²) in combination with doxorubicin and cyclophosphamide (CAP regimen)
Trial: 29417092
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), 10 hours of treatment
Trial: 29417092
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (various sedation methods)
Trial: 29419425
Drug: Plerixafor (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (dose escalation)
Trial: 29420116
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (PCV7)
Trial: 29420467
Drug: Neratinib (pan-HER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (pan-HER kinase inhibitor)
Trial: 29420795
Drug: Opioid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid therapy in younger patients (<50 years)
Trial: 29420795
Drug: Opioid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid therapy in older patients (50-64 years)
Trial: 29420795
Drug: Opioid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid therapy in younger and older patients
Trial: 29421974
Drug: Stanford Leisure-Time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanford Leisure-Time Activity Categorical Item (L-Cat)
Trial: 29421974
Drug: L-Cat and
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Cat and adapted GLTEQ measures
Trial: 29422881
Drug: Wrist-worn activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist-worn activity tracking device providing multimodal feedback on daily arm use for 6 weeks
Trial: 29424480
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers
Trial: 29426386
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and task-oriented training
Trial: 29428177
Drug: Caregiver or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver or adolescent attitudes and beliefs about on-schedule HPV vaccination or HPV vaccine safety
Trial: 29428178
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen of qHPV vaccine
Trial: 29428183
Drug: Mass azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mass azithromycin treatment (coverage rate of 84%)
Trial: 29428788
Drug: N.I.R. H.E.G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N.I.R. H.E.G. neurofeedback training
Trial: 29429815
Drug: JE-VC (2nd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-VC (2nd booster dose)
Trial: 29429815
Drug: JE-MB (1st
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-MB (1st booster dose)
Trial: 29429815
Drug: JE-VC (1st
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-VC (1st booster dose)
Trial: 29430250
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shock wave therapy (5 outpatient sessions)
Trial: 29430278
Drug: L-AVA group
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-AVA group
Trial: 29431735
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment with dichloroacetate (DCA)
Trial: 29433560
Drug: Insulin-treated T1DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-treated T1DM patients
Trial: 29433560
Drug: Insulin-treated T2DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-treated T2DM patients
Trial: 29433573
Drug: GH-treated patients
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-treated patients (GH dose 0.30±0.16 mg/day for females and 0.25±0.10 mg/day for males)
Trial: 29435776
Drug: Anagliptin 100
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anagliptin 100 mg orally twice per day
Trial: 29435776
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg orally once per day
Trial: 29435872
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with weekly paclitaxel (50 mg/m²) and carboplatin, radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx)
Trial: 29435872
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin
Trial: 29437593
Drug: Current immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current immunosuppressive therapies for SR-aGVHD
Trial: 29437753
Drug: Multiplex assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART)
Trial: 29438361
Drug: AZD0424 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0424 (5 mg to 150 mg once-daily or 40 mg bi-daily)
Trial: 29438361
Drug: AZD0424 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0424 (doses above 60 mg per day)
Trial: 29439003
Drug: Tumour necrosis
RxNorm normalized name: Tumour necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour necrosis factor inhibitors (TNFi)
Trial: 29439003
Drug: Follow-up at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up at 14-16 weeks after treatment initiation
Trial: 29439084
Drug: CYP1A2 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP1A2 activity measured after administration of caffeine
Trial: 29439084
Drug: CYP2B6 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2B6 activity measured after administration of bupropion
Trial: 29439084
Drug: CYP2C9 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C9 activity measured after administration of tolbutamide
Trial: 29439084
Drug: CYP2C19 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 activity measured after administration of omeprazole
Trial: 29439084
Drug: CYP2D6 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 activity measured after administration of dextromethorphan
Trial: 29439084
Drug: CYP2E1 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2E1 activity measured after administration of chlorzoxazone
Trial: 29439084
Drug: CYP3A4/5 activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A4/5 activity measured after administration of midazolam
Trial: 29439186
Drug: BGB-3111 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-3111 and PD-1 antibody
Trial: 29439670
Drug: Next-generation DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Next-generation DNA vaccine targeting antigen-presenting cells (APCs) with a sequence encoding a chemokine (MIP-3α)
Trial: 29439670
Drug: Next-generation DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Next-generation DNA vaccine
Trial: 29439971
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg/day) and Ribavirin (1,000 to 1,200 mg/day) for 3 to 52 weeks
Trial: 29440154
Drug: Traditional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional surgical treatment (full sternotomy)
Trial: 29440154
Drug: Transcatheter surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter surgical treatment
Trial: 29440404
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for 4 weeks, intensive daily sessions.
Trial: 29443701
Drug: Polypharmacy (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (5 or more unique medications)